Clinical trial
Combining Gene Editing and iPS to Study and Treat Monogenic Autoinflammatory Diseases
NCT07889947 is registered in ClinicalTrials.gov with Istituto Giannina Gaslini as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Combining Gene Editing and iPS to Study and Treat Monogenic Autoinflammatory Diseases
- Lead sponsor
- Istituto Giannina Gaslini
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- March 25, 2026
- Completion date
- December 31, 2026
- Enrollment
- 6 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
autoinflammatory disease, type 1 interferonopathies
Arms
As registered; 2 arms.
-
A patient with a genetically confirmed diagnosis of STING-associated vasculopathy
-
case controls
Primary endpoints
Registered primary outcome measures; 1 primary.
-
To generate a model of type I interferonopathy to gain insight in STING1 role in nonhematopoietic cells and to explore gene editing as a therapeutic option
Lead sponsor's other trials
Istituto Giannina Gaslini, most recent start first.
+48 more trials See the organization page